Laboratory detection of the antiphospholipid syndrome via calibrated automated thrombography

Summary

Lupus anticoagulants (LAC) consist of antiphospholipid antibodies, detected via their anticoagulant properties in vitro. Strong LAC relate to thromboembolic events, a hallmark of the anti-phospholipid syndrome. We have analyzed whether detection of this syndrome would benefit from thrombin generation measurements. Therefore, calibrated automated thrombography was done in normal plasma (n=30) and LAC patient plasma (n=48 non-anticoagulated, n=12 on oral anticoagulants), diluted 1:1 with a normal plasma pool. The anti-β₂-glycoprotein I monoclonal antibody 23H9, with known LAC properties, delayed the lag time and reduced the peak height during thrombin generation induction in normal plasma dose-dependently (0–150 μg/ml). At variance, LAC patient 1:1 plasma mixtures manifested variable lag time prolongations and/or peak height reductions. Coupling these two most informative thrombin generation parameters in a peak height/lag time ratio, and upon normalization versus the normal plasma pool, this ratio distributed normally and was reduced in the plasma mixtures, for 59/60 known LAC plasmas. The normalized peak height/lag time ratio correlated well with the normalized dilute prothrombin time, diluted Russell’s viper venom time and silica clotting time, measured in 1:1 plasma mixtures (correlation coefficients 0.59–0.72). The anticoagulant effects of activated protein C (0–7.5 nM) or 23H9 (0–150 μg/ml), spiked in the 1:1 LAC plasma mixtures were reduced for the majority of patients, compatible with functional competition between patient LAC and activated protein C and LAC and 23H9, respectively. Hence, the normalized thrombin generation-derived peak height/lag time ratio identifies LAC in plasma with high sensitivity in a single assay, irrespective of the patient’s treatment with oral anticoagulants.

Keywords

Thrombosis - α₂-glycoprotein I - lupus anticoagulants - prothrombin - antibodies

• References

• 1 de Groot PG, Derksen RHWM. Pathophysiology of the antiphospholipid syndrome. J. Throm Haemost 2005; 03: 1854-1860.
• 2 Miyakis S, Lockshin MD, Atsumi D. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 04: 295-306.
• 3 Giannakopoulos B, Passam F, Rahgozar S. et al. Current concepts on the pathogenesis of the antiphospholipid syndrome. Blood 2007; 109: 422-430.
• 4 Arnout J, Wittevrongel C, Vanrusselt M. et al. Beta-2-glycoprotein I dependent lupus anticoagulants from stable bivalent antibody beta-2-glycoprotein I complexes on phopholipid surfaces. Thromb Haemost 1998; 79: 79-86.
• 5 Jankowski M, Vreys I, Wittevrongel C. et al. Thrombogenicity of β₂-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101: 157-162.
• 6 de Laat B, Derksen RHWM, De Groot PG. High-avidity anti-β₂-glycoprotein I antibodies highly correlate with thrombosis in contrast to low-avidity anti-β₂-glycoprotein I antibodies. J Thromb Haemost 2006; 04: 1619-1621.
• 7 Zoghlami-Rintelen C, Vormittag R, Sailor T. et al. The presence of IgG antibodies against beta-2-glycoprotein I predicts the risk of thrombosis in patients with lupus anticoagulant. J Thromb Haemost 2005; 03: 1160-1165.
• 8 Amengual O, Atsumi T, Koike T. Specificities, properties, and clinical significance of antiprothrombin antibodies. Arthritis Rheum 2003; 48: 886-895.
• 9 Pennings MTT, Derksen RHWM, Van Lummel M. et al. Platelet adhesion to dimeric β₂-glycoprotein I under conditions of flow is mediated by at least two receptors: glycoprotein Ibα and apolipoprotein E receptor 2’. J Thromb Haemost 2007; 05: 369-377.
• 10 de Laat B, Wu X-X, Van Lummel M. et al. Correlation between antiphospholipid antibodies that recognize domain I of β₂-glycoprotein I and a reduction in the anticoagulant activity of Annexin A5. Blood 2007; 109: 1490-1494.
• 11 Hemker HC, Al Dieri RA, De Smedt E. et al. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost 2006; 96: 553-561.
• 12 Liestol S, Sandset PM, Jacobsen EM. et al. Decreased anticoagulant response to tissue factor pathway inhibitor type 1 in plasma from patients with lupus anticoagulants. Br J Haematol 2006; 136: 131-137.
• 13 Devreese K, Wijns W, Combes I. et al. Thrombin generation in plasma of healthy adults and children: chromogenic vs. fluorogenic thrombogram analysis. Thromb Haemost 2007; 98: 600-613.
• 14 Hemker HC, Giesen P, Al Dieri R. et al. Calibrated automated TG measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
• 15 Franchini M, Veneri D, Salvagno GL. et al. Inherited thrombophilia. Critical Rev Clin Lab Sci 2006; 43: 249-290.
• 16 Brandt JT, Triplett DA, Alving B. et al. Criteria for diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Anti-phospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
• 17 Arnout J. Antiphospholipid syndrome: Diagnostic aspects of lupus anticoagulants. Thromb Haemost 2001; 86: 83-91.
• 18 Devreese K. Interpretation of normal plasma mixing studies in the laboratory diagnosis of lupus anticoagulants. Thromb Res 2007; 119: 369-376.
• 19 Triplett DA, Barna LK, Unger GA. A hexagonal (II) phase phopholipid neutralization assay for lupus anticoagulant identification. Lupus 1994; 03: 281-287.
• 20 Nojima J, Kuratsune H, Suehisa E. et al. Acquired activated protein C resistance associated with IgG antibodies against β₂-glycoprotein I and prothrombin as strong risk factor for venous thromboembolism. Clin Chem 2005; 51: 545-552.
• 21 Regnault V, Béguin S, Wahl D. et al. Thrombography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost 2003; 89: 208-212.
• 22 Liestol S, Sandset PM, Mowinckel M-C, Wisloff F. Activated protein C resistance determined with a thrombin generation-based test is associated with thrombotic events in patients with lupus anticoagulants. J Thromb Haemost 2007; 05: 2204-2210.
• 23 Chantarangkul V, Clerici M, Bressi C. et al. Thrombin generation assessed as endogenous thrombin potential in patients with hyper-or hypo-coagulability. Haematologica 2003; 88: 547-554.
• 24 Brummel-Ziedings KE, Vossen CY, Butenas S. et al. Thrombin generation profiles in deep venous thrombosis. J Thromb Haemost 2005; 03: 2497-2505.
• 25 Sheng Y, Hanly JG, Reddel SW. et al. Detection of antiphospholipid antibodies: a single chromogenic assay of thrombin generation sensitively detects lupus anticoagulants, anticardiolipin antibodies, plus antibodies binding β₂-glycoprotein I and prothrombin. Clin Exp Immunol 2001; 124: 502-508.
• 26 Hangly JG, Smith SA. Anti- β₂-glycoprotein I antibodies, in vitro thrombin generation, and the anti-phospholipid syndrome. J Rheumatol 2000; 27: 2152-2159.
• 27 Galli M, Luciani D, Bertolini G. et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832.
• 28 Gardiner C, Cohen H, Jenkins A. et al. Detection of acquired resistance to activated protein C associated with antiphospholipid antibodies using a novel clotting assay. Blood Coagul Fibrinolysis 2006; 17: 477-483.
• 29 Ofosu FA. Review: Laboratory markers quantifying prothrombin activation and actions of thrombin in venous and arterial thrombosis do not accurately assess disease severity or the effectiveness of treatment. Thromb Haemost 2006; 96: 568-577.